Skip to Content

Analysts have given Sage Therapeutics, Inc. (NASDAQ:SAGE) a consensus rating of “Hold.”

Analysts have given Sage Therapeutics, Inc. (NASDAQ:SAGE) a consensus rating of “Hold.”

According to information made available by Bloomberg Ratings, the fifteen rating agencies presently keeping an eye on Sage Therapeutics, Inc. (NASDAQ: SAGE) have collectively assigned a “Hold” rating to the company as their recommendation for how investors should proceed with the stock. There have been recommendations from three different analysts to purchase the stock; from eight different experts, there have been recommendations to hold the stock; and from one different analyst, there has been a recommendation to sell the shares. The brokerage firms have, on average, assigned the stock the rating of “hold” over the past year, and the average price objective for the stock over the next year is $48.31.

Recently, a significant number of equity professionals have been holding discussions about SAGE’s stock. On November 1 November 1, Loop Capital published its initial research note on Sage Therapeutics, the company it will be monitoring. They suggested maintaining stock ownership while establishing a price objective for the company of $41.00 per share. Morgan Stanley lowered their price target for Sage Therapeutics in a research report published on November 21 and 21. The report was about the company. The new price target set by the company is now $50.00, and the company has given it an “equal weight” rating. Sage Therapeutics was downgraded by the investment research firm StockNews.com from a “hold” recommendation to a “sell” rating in a company report published on January 5. HC Wainwright gave the company a “neutral” rating in a report that was made public on November 9 and November 9, and they lowered their price objective for Sage Therapeutics from $55.00 to $50.00 as a result of this rating. In addition to that, they provided the company with this new price target. The target price for Sage Therapeutics was lowered from $43.00 to $40.00 in a research report made public by BMO Capital Markets on November 9. Additionally, the company was given a rating of “market perform.”

Recently, institutional investors have altered how they have been keeping their shares of the company in their portfolios. MetLife Investment Management LLC made a purchase of stock in Sage Therapeutics for the amount of $34,000 during the first three months of 2018. Nisa Investment Advisors LLC increased the amount of Sage Therapeutics stock owned by 1,629.2% during the second quarter of 2018. Following the acquisition of an additional 1,450 shares during the most recent quarter, Nisa Investment Advisors LLC now holds 1,539 shares of the biopharmaceutical company’s stock. Each of these shares has a current market value of $50,000, making the firm’s investment in the stock worth $50,000. In the second quarter, US Bancorp DE increased the proportion of Sage Therapeutics stock owned by 32.5 percent. As a result of the purchase of an additional 457 shares during the period, the total number of shares held by US Bancorp DE has increased to 1,863 shares, which has increased in value to $60,000. This brings the total value of the shares that US Bancorp DE presently possesses to $60,000, bringing the total number of shares that it possesses to a total of Exchange Traded Concepts LLC increased the number of Sage Therapeutics shares it owns by 183.4% during the second quarter, bringing the total number of shares it owns to 1.34 million. Exchange Traded Concepts LLC now owns a total of 2,403 shares of the biopharmaceutical company’s stock, valued at $78,000, after purchasing an additional 1,555 shares. During the period in question, these shares were purchased. Sage Therapeutics was the recipient of new capital for approximately $98,000 invested by Great West Life Assurance Company of Canada during the third quarter. This was the only significant investment that the company had made. The company’s outstanding shares are currently owned by hedge funds and other institutional investors, who account for 85.60 percent of the total.

When trading started on Wednesday, the cost of a single share of Sage Therapeutics was $44.04 per share. Over the past year, the price of Sage Therapeutics has fluctuated between $27.36 and $49.56 at various points, reaching a low of $27.36 and a high of $49.56. The company’s moving average price over the previous 50 days is $39.17, and the moving average price over the previous 200 days is $38.67. The company has a price-to-earnings ratio of -5.10, a beta value of 1.17, and a market capitalization of $2.62 billion.

On November 8 November 8, the most recent quarterly earnings report for Sage Therapeutics, which is traded on the NASDAQ under the symbol SAGE, was made public. The biopharmaceutical company’s earnings per share for the quarter came in at $2.31, which was $0.15 less than the average expectation of $2.16. In their financial statements, Sage Therapeutics disclosed a loss in return on equity of 32.76% and a negative net margin of 7.895.27%. The sales for the company for the quarter came in significantly higher than the predictions of the analysts, which were 1.68 million dollars, coming in instead at 1.74 million dollar quarter, for the biopharmaceutical company came in at $2.31, which was $0.15 less than the average expectation of $2.16. In their financial statements, Sage Therapeutics disclosed a loss in return on equity of 32.76% and a negative net margin of 7.895.27%. The sales for the company for the quarter came in significantly higher than the analysts’ predictions, which were 1.68 million dollars, coming in instead at 1.74 million dollars. According to projections made by analysts covering the pharmaceutical industry, Sage Therapeutics will end the current fiscal year with a loss of 8.9 cents per share.

Sage Therapeutics, Inc. is a biopharmaceutical company that develops and markets medications to treat disorders affecting the central nervous system. These disorders include Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The company’s primary focus is on Zulresso as a product candidate. It is a formulation of brexanolone that is administered intravenously, and its intended use is to treat postpartum depression (PPD) in adults. Zuranolone is a neuroactive steroid that is currently being investigated for use in the treatment of PPD, major depressive disorders, treatment-resistant disorders, generalized anxiety disorders, and bipolar depression in clinical trials that are in the Phase III testing phase. In Phase II clinical trials, the drug SAGE-324 is being investigated for its potential to treat essential tremors. In addition, the company has a medication undergoing clinical trials to treat generalized anxiety disorders and bipolar depression.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *